Forbes January 12, 2021
The huge push for a vaccine based on messenger RNA (mRNA) against Covid-19 is beginning to bear fruit, and promises to be a revolution in the fight against infectious diseases.
Moderna, a biotechnology company dedicated exclusively to mRNA-based vaccine development (its original name was written ModeRNA and referred precisely to its work with modified RNA), says it is applying the same techniques it developed to obtain its Covid-19 vaccine — already approved around the world — to develop new vaccines for seasonal flu, HIV and the Nipah virus, along with combination vaccines for both flu and Covid-19.
What does the work with mRNA that is behind both Moderna’s and Pfizer’s vaccine with its German partner BioNTech mean technologically, and how does it differ from...
Today's Sponsors
Today's Sponsor